iShares Biotech Index ETF: The Best Way to Invest in Biotech
Sometimes, you just need to put events into perspective.
Not everyone possesses this valuable ability, but my brother is very good at it. Whenever pressure from work gets to him and he finds himself (or other people) stressed, he likes to say, “You’re either curing cancer or you’re not.”
This is a guy who writes advertising copy for the movie industry for a living. He won’t find a cure for cancer there and understands that most of the time, he’s not going to impact people’s lives in a meaningful way.
But as a movie buff and film scholar, he loves his work and is very good at what he does. His job is simply to help sell movie tickets – and that sense of perspective helps relieve the stress when things become intense.
But with the healthcare sector, that perspective is turned on its head – and it’s one of the reasons I love following the group – and in particular, biotech stocks.
After all, these companies are trying to cure cancer… multiple sclerosis… diabetes… Alzheimer’s Disease… heart disease. The list goes on. It’s exciting and emotional. And who wouldn’t want to invest in a company on the verge of a new therapy for a horrible disease?
Here’s a very simple way for you to do that…
An Explosive 10 Years For Biotech
336% Returns And An Extra $15,000 In Your Portfolio
Last week, I had the privilege of speaking at the 10th annual Investment U conference in St. Petersburg, Florida. During my presentation, I discussed how investors need to be aware that early-stage biotech stocks trade on emotion as much as fundamentals.
It’s one of the factors that has led the biotech sector to outperform the S&P 500 over the past decade. The numbers prove it. While the S&P 500 has returned a measly 19.8% cumulatively over the past 10 years – and that number roughly doubles if you include dividends – the Amex Biotechnology Index [AMEX: ^BTK] returned 336.3% over the same period. That’s some outperformance!
I talked about how investors should consider diversifying their portfolio to include biotech stocks – and the best ways to do that. And the benefit of doing so speak for themselves…
Over the past 10 years, a $100,000 portfolio invested in the S&P 500 would now be worth about $141,000. However, if just 5% of that portfolio were allocated to biotech stocks, the portfolio would be worth over $156,000. That’s an extra $15,000 in returns from just 5% of the portfolio.
Here’s a quick n’ easy way to get some biotech exposure…
The Best Way To Buy Biotech
First of all, forget mutual funds. In particular, biotech sector mutual funds have not impressed me over the years, as they tend to be expensive and the performance has been lacking.
These days, ETFs are the dynamic new wave of funds – a subject that my colleague and technical wizard Jim Stanton focuses on here every other Monday in his new “Sector Watch” column. When you have a moment, check it out here – it’s good stuff.
If you want some simple biotech exposure via ETFs, the iShares Nasdaq Biotech Index (Amex: IBB) is an inexpensive way to give your portfolio some biotech diversification, since it tracks the performance of the stocks in the Nasdaq Biotechnology Index.
Two quick points to note, though:
- Biotech stocks tend to drop in the summer, so if you keep the sector on your radar, you may have an opportunity to get in at lower prices.
- While biotech stocks can definitely pay off handsomely, understand that the sector has above average risk, so make sure it doesn’t make up too large a portion of your portfolio.
Amgen (Nasdaq: AMGN), Gilead Sciences (Nasdaq: GILD), Celgene (Nasdaq: CELG) and BioMarin (Nasdaq: BMRN) are all members of the Index. Investing in an ETF like this gives you an easy, cheaper and lower risk way to invest in the biotech sector. Of course, make sure you do your due diligence before investing and be sure to allocate a sensible portion of your capital to any investment. As the old investment adage goes, “Never risk more than you can afford to lose.”
Related Articles:
- 'When There's Blood in the Streets', Buy Biotech Stocks »
- Federal Circuit Affirms Merck’s Victory in Trusopt/Cosopt Case »
- Viropharma, Lev Pharmaceuticals: An Attractive Biotech Pair »
- Sequenom Down on Threat of Competition »
- Four Value Priced Stocks: Sysco, Eli Lilly, PepsiCo and Johnson & Johnson »
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
ETFs In Focus
-
Editor's Picks
-
Most Popular
- Reading the S&P 500's Crashing Waves
- On a Return to Normalcy: Dow 8,500
- Looking Back at Lehman: Lying, Scapegoating and a General Lack of Accountability
- iShares ETF Tracking Error: Risks and Explanations
- U.S. vs. the World: Sectors Matter
- Global Stock Markets: The Crash of 2008?
- Full list of Editor's Picks »
- Nation's Debt: It's Not Being Rescued, It's Being Moved Around »
- Crazy P/E Ratios »
- Clueless - Cramer's Mad Money (10/8/08) »
- Wall Street Breakfast: Must-Know News »
- Cramer: Dow Could Drop Another 14%, Oil's Going to $50 »
- Roger Wiegand: 'Severe Bull Market' Ahead for Gold »
- Awaiting Apple Earnings and Guidance »
- Four Ways to Protect Money During the Fallout »
- Ford, GM on the Chopping Block? »
- Earnings Preview: General Electric »
- Cramer Should Be Suspended »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- 'When There's Blood in the Streets', Buy Biotech Stocks
- Midstream MLPs Crashing, Present Opportunity
- A Fresh Look at Shipping Company Stocks
- Panic Selling in InterOil: What Now?
- Potash Corp.: No Liquidity Problems Here
- The Year of the Bear
- Cobalt: More Than Just Blue
- Investors Can Find Comfort in Big Blue
- Hershey: The Perfect Recession Investment?
- Applied Materials Leads by Example
- Full list of Long Ideas »
- The Short Case for General Electric
- Too Late to Short SPY? An Historical Perspective
- Henderson Group: Profit Warning Surprises Short Investors
- Decreasing Chipotle Traffic Could Spell Trouble
- Why I Sold Lowe's Short
- Accor, Host and Marriott: Short Interest Heats Up
- Global Financial Crisis Makes Oil a Great Hedge
- Michael Page International: Stock Down on Market Weakness
- Gaming Stocks Still a Poor Bet - Barron's
- After Coming Rate Cuts, Some Appealing Short ETFs
- Full list of Short Ideas »
- Clueless - Cramer's Mad Money (10/8/08)
- Torpedo Dry Ships - Cramer's Lightning Round (10/8/08)
- Chocolate Lover - Cramer's Mad Money (10/7/08)
- Yield is King - Cramer's Lightning Round (10/7/08)
- Goldman Disses Solar - Cramer's Stop Trading ! (10/7/08)
- Time to Hoard Cash - Cramer's Mad Money (10/6/08)
- Buyers On Strike - Cramer's Stop Trading! (10/6/08)
- Still Bullish on RIMM - Cramer's Lightning Round (10/6/08)
- The Cramer Crash?
- Cramer: Dow Could Drop Another 14%, Oil's Going to $50
- Full list of Cramers Picks »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »



